Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide. NEX-22 is a new promising treatmen ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

Previously, Rybelsus — an approved diabetes drug in pill form — was also used for weight loss by patients in India. Launched ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

The 2.5 mg vial is priced at 3,500 rupees ($40.5 ... banking on generics of an earlier generation of obesity treatment, a liraglutide injectable sold by Novo Nordisk as Saxenda.